{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:15:23Z","timestamp":1791976523488,"version":"4.4.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T00:00:00Z","timestamp":1621900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      The International Cooperative Growth Study, NutropinAq\n                      <jats:sup>\u00ae<\/jats:sup>\n                      European Registry (iNCGS) (NCT00455728) monitored long-term safety and effectiveness of recombinant human growth hormone (rhGH; NutropinAq\n                      <jats:sup>\u00ae<\/jats:sup>\n                      [somatropin]) in paediatric growth disorders.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Open-label, non-interventional, post-marketing surveillance study recruiting children with growth disorders. Endpoints included gain in height standard deviation score (SDS), adult height, and occurrence of adverse events (AEs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>2792 patients were enrolled. 2082 patients (74.6%) had growth hormone deficiency (GHD), which was isolated idiopathic in 1825 patients (87.7%). Non-GHD diagnoses included Turner syndrome (TS) (n=199), chronic renal insufficiency (CRI) (n=10), other non-GHD (n=498), and missing data for three participants. Improvements from baseline height SDS occurred at all time points to Month 132, and in all subgroups by disease aetiology. At Month 12, mean (95% CI) change in height SDS by aetiology was: idiopathic GHD 0.63 (0.61;0.66), organic GHD 0.71 (0.62;0.80), TS 0.59 (0.53; 0.65), CRI 0.54 (-0.49;1.56), and other non-GHD 0.64 (0.59;0.69). Mean height ( \u00b1 SD) at the last visit among the 235 patients with adult or near-adult height recorded was 154.0\u00a0cm ( \u00b1 8.0) for girls and 166.7 cm\u00a0( \u00b1 8.0) for boys. The most frequent biological and clinical non-serious drug-related AEs were increased insulin-like growth factor concentrations (314 events) and injection site haematoma (99 events). Serious AEs related to rhGH according to investigators were reported (n=30); the most frequent were scoliosis (4 events), epiphysiolysis (3 events), and strabismus (2 events).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>There was an improvement in mean height SDS in all aetiology subgroups after rhGH treatment. No new safety concerns were identified.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2021.676083","type":"journal-article","created":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T02:08:31Z","timestamp":1621908511000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Effectiveness and Overall Safety of NutropinAq\u00ae for Growth Hormone Deficiency and Other Paediatric Growth Hormone Disorders: Completion of the International Cooperative Growth Study, NutropinAq\u00ae European Registry (iNCGS)"],"prefix":"10.3389","volume":"12","author":[{"given":"Regis","family":"Coutant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Bosch Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina Patricia","family":"Dumitrescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Schnabel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Sert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Perrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehul","family":"Dattani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,5,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1210\/edrv.19.2.0329","article-title":"The Diagnosis of Growth Hormone Deficiency in Children and Adults","volume":"19","author":"Shalet","year":"1998","journal-title":"Endocr Rev"},{"key":"B2","article-title":"[Growth Hormone Deficiency in Children]","volume":"177","author":"Nielsen","year":"2015","journal-title":"Ugeskr Laeger"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.96.12.zega35","article-title":"Patient Information Page From The Hormone Foundation. Growth Hormone Deficiency in Children","volume":"96","author":"Castro","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B4","doi-asserted-by":"crossref","DOI":"10.1038\/ncpendmet0169","article-title":"Use of Growth Hormone in Children","volume":"2","author":"Hindmarsh","year":"2006","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"B5","article-title":"Idiopathic Growth Hormone Deficiency: MR Findings in 35 Patients","volume":"12","author":"Abrahams","year":"1991","journal-title":"AJNR Am J Neuroradiol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1159\/000452150","article-title":"Guidelines for Growth Hormone and Insulin-Like Growth Factor-I Treatment in Children and Adolescents: Growth Hormone Deficiency, Idiopathic Short Stature, and Primary Insulin-Like Growth Factor-I Deficiency","volume":"86","author":"Grimberg","year":"2016","journal-title":"Horm Res Paediatr"},{"key":"B7","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.ecl.2009.06.006","article-title":"Growth Hormone: The Expansion of Available Products and Indications","volume":"38","author":"Franklin","year":"2009","journal-title":"Endocrinol Metab Clin North Am"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199910143411607","article-title":"Growth Hormone Therapy in Adults and Children","volume":"341","author":"Vance","year":"1999","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1159\/000322881","article-title":"Treatment of Growth Hormone-Deficient Infants With Recombinant Human Growth Hormone to Near-Adult Height: Patterns of Growth","volume":"75","author":"Root","year":"2011","journal-title":"Horm Res Paediatr"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0b013e3283081911","article-title":"Safety and Efficacy of Growth Hormone Treatment in Small for Gestational Age Children","volume":"15","author":"Poduval","year":"2008","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"B11","doi-asserted-by":"crossref","DOI":"10.1542\/peds.102.S3.479","article-title":"Growth Hormone Treatment of Girls With Turner Syndrome: The National Cooperative Growth Study Experience","volume":"102","author":"Plotnick","year":"1998","journal-title":"Pediatrics"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/BF00866726","article-title":"Recombinant Human Growth Hormone in Infants and Young Children With Chronic Renal Insufficiency. Genentech Collaborative Study Group","volume":"9","author":"Fine","year":"1995","journal-title":"Pediatr Nephrol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-1829","article-title":"Growth Hormone Treatment in Short Children Born Prematurely-Data From KIGS","volume":"96","author":"Boguszewski","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2019-00775","article-title":"Treatment of Children With GH in the United States and Europe: Long-Term Follow-Up From NordiNet(R) IOS and ANSWER Program","volume":"104","author":"Savendahl","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.17458\/per.vol16.2018.25yearsghdata","article-title":"National Cooperative Growth Study: 25 Years of Growth Hormone Data, Insights, and Lessons for Future Registries","volume":"16","author":"Bell","year":"2018","journal-title":"Pediatr Endocrinol Rev"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-01189","article-title":"Safety Outcomes During Pediatric GH Therapy: Final Results From the Prospective GeNeSIS Observational Program","volume":"104","author":"Child","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-2302","article-title":"Pfizer International Growth Database International B. Factors Predicting the Near-Final Height in Growth Hormone-Treated Children and Adolescents With Chronic Kidney Disease","volume":"93","author":"Nissel","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B18","unstructured":"Summary of Product Characteristics"},{"key":"B19","first-page":"P1","article-title":"International Cooperative Growth Study, Nutropinaq\u00ae European Registry (iNCGS): Countries Specificities","volume":"86","author":"Coutant","year":"2016","journal-title":"ESPE Abstr"},{"key":"B20","first-page":"P1","article-title":"Year-One Effectiveness and Overall Safety of NutropinAq for Growth Hormone Deficiency (GHD) and Other Paediatric Growth Disorders: Completion of the International Cooperative Growth Study (Incgs) European Registry","volume":"89","author":"Coutant","year":"2018","journal-title":"ESPE Abstr"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(52)80205-7","article-title":"Tables for Predicting Adult Height From Skeletal Age: Revised for Use With the Greulich-Pyle Hand Standards","volume":"40","author":"Bayley","year":"1952","journal-title":"J Pediatr"},{"key":"B22","volume-title":"Auxologie, M\u00e9thode Et S\u00e9quences","author":"Semp\u00e9","year":"1979"},{"key":"B23","first-page":"45","article-title":"The LMS Method for Constructing Normalized Growth Standards","volume":"44","author":"Cole","year":"1990","journal-title":"Eur J Clin Nutr"},{"key":"B24","unstructured":"Referenzperzentile F\u00fcr Anthropometrische Ma\u00dfzahlen Und Blutdruck Aus der Studie"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s001120170107","article-title":"Perzentile F\u00fcr Den Body-mass-Index F\u00fcr Das Kindes Und Jugendalter Unter Heranziehung Verschiedener Deutscher Stichproben","volume":"149","author":"Kromeyer-Hauschild","year":"2001","journal-title":"Monatsschrift Kinderheilkunde"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab080","article-title":"Long-Term Safety of Growth Hormone Treatment in Childhood: Two Large Observational Studies NordiNet (R) IOS and ANSWER","volume":"106","author":"Savendahl","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(20)30163-7","article-title":"Long-Term Mortality After Childhood Growth Hormone Treatment: The SAGhE Cohort Study","volume":"8","author":"Savendahl","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.9778\/cmajo.20180020","article-title":"Growth Hormone Treatment of Canadian Children: Results From the GeNeSIS Phase IV Prospective Observational Study","volume":"6","author":"Deal","year":"2018","journal-title":"CMAJ Open"},{"key":"B29","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3760\/cma.j.issn.0578-1310.2009.01.012","article-title":"[Efficacy and Safety of Recombinant Human Growth Hormone Solution in Children With Growth Hormone Deficiency in China: A Multicenter Trial]","volume":"47","author":"Hou","year":"2009","journal-title":"Zhonghua Er Ke Za Zhi"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-2513","article-title":"Efficacy and Safety Results of Long-Term Growth Hormone Treatment of Idiopathic Short Stature","volume":"90","author":"Kemp","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"B31","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1007\/s00467-003-1158-5","article-title":"Chronic Renal Insufficiency in Children: The 2001 Annual Report of the NAPRTCS","volume":"18","author":"Seikaly","year":"2003","journal-title":"Pediatr Nephrol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-007-0497-z","article-title":"Use of rhGH in Children With Chronic Kidney Disease: Lessons From NAPRTCS","volume":"22","author":"Seikaly","year":"2007","journal-title":"Pediatr Nephrol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.676083\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T07:44:57Z","timestamp":1672213497000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.676083\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,25]]},"references-count":32,"alternative-id":["10.3389\/fendo.2021.676083"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2021.676083","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,25]]},"article-number":"676083"}}